IMR Press / FBL / Volume 14 / Issue 5 / DOI: 10.2741/3329

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Poly (ADP-ribose) glycohydrolase (PARG) and its therapeutic potential
Show Less
1 Leibniz Institute of Age Research - Fritz Lipmann Institute (FLI), 07745 Jena, Germany
2 Faculty of Biology and Pharmacy, Friedrich Schiller University Jena, 07743 Jena, Germany
Academic Editor:Michael Hottiger
Front. Biosci. (Landmark Ed) 2009, 14(5), 1619–1626; https://doi.org/10.2741/3329
Published: 1 January 2009
(This article belongs to the Special Issue ADP-riboseNAD metabolism)
Abstract

Poly (ADP-robose) glycohydrolase (PARG) is a catabolic enzyme that cleaves ADP-ribose polymers synthesized by members of the poly (ADP-ribose) polymerase (PARP) family of enzymes. The growing evidence supports the importance of a tight control of poly (ADP-ribose) metabolism by the two major enzymes, PARP-1 and PARG. Recent studies have advanced the understanding of PARPs' and PARG's functions in various cellular and physiological processes. In the last 10 years, homeostasis of poly (ADP-ribosyl)ation has been a target of pharmaceutical interventions for various pathologies. Although the polymer synthesizing enzyme PARP-1 has been well studied, the function of PARG remains largely unknown. However, a great effort has been made in recent years to delineate biological functions of PARG and to explore the therapeutical potentials of PARG inhibition in pathophysiological conditions such as inflammation, ischemia, stroke, and cancer chemotherapy.

Share
Back to top